戻る
Virax Biolabs Group Ltd (VRAX) 収入
VRAX 株価推移チャート
VRAX 収入
Virax Biolabs Group Ltd
$0.19
-9.95%
$-0.02
終値： Apr 01, 16:00:00 GMT-4
$0.21
6.06%
$0.01
アフターマーケット：Apr 01, 20:00:00 GMT-4
データなしEarnings FAQ
VRAXの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Virax Biolabs Group Ltd VRAXの前四半期の収益はどうでしたか？
Virax Biolabs Group Ltdの収益見積もりはいくらですか？
Virax Biolabs Group Ltdの収益品質スコアはどれくらいですか？
Virax Biolabs Group Ltdはいつ収益を報告しますか？
Virax Biolabs Group Ltdの予想収益はいくらですか？
Virax Biolabs Group Ltdは収益予想を上回りましたか？
主要データ
前終値
$0.2199
始値
$0.19
当日レンジ
$0.166 - $0.21
52週レンジ
$0.152 - $1.34
取引高
7.9M
平均取引高
4.1M
配当利回り
--
1株当たり利益(TTM)
-1.25
時価総額
$1.5M
VRAXとは何ですか？
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).